The long term data would be very important to the FDA. The reason been that it provides long term survival data not so much as a resalt of efficacy but the progesstion or not of desease. We see that after 2 years relapse of desease resalting in death is very low. This was not known before today.
We have saved lives of children and we now know the majority should go on living life as normal healthy adolts .
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-29
-
- There are more pages in this discussion • 327 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |